Werkgroep Cardiologische centra Nederland

GEMINI (Completed)

A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects with ACS
Medicine
rivaroxaban
Population
ASCVD
Phase
II
Starting year
2014
More information
ClinicalTrials.gov

Director of Study

dr. M.W.J. van Hessen (Cardioloog)
Gouda, Groene Hart Ziekenhuis

Publications: GEMINI

  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialLancet - Abstract - Cornel, dr. J.H. - GEMINI - ASCVD

Publications by WCN study

Publications WCN studies by WCN member